Browse by Countries

Request/Offer Detail

Title: Differential diagnosis of dementia with Lewy bodies and Parkinson's disease
TypeName: Technology Offer
Request Date:2016/04/28
Country: Germany
Summary: German scientists developed a new diagnostic approach to differentiate between Dementia with Lewy bodies (DLB), Parkinson's disease (PD) and other neuropathies. They are looking for commercializing and licensing partners in the diagnostic field.
Description: Parkinson's disease (PD) is a neurodegenerative disorder affecting about 1% of the population over 65 years. Atypical Parkinson syndrome arise generally from other neurodegenerative diseases like Dementia with Lewy bodies (DLB). The accurate distinction between Parkinson's disease, dementia with Lewy bodies and other non-alpha-synuclein variants with Parkinson syndrome is challenging due to an overlap of clinical symptoms and neuropathological changes. University scientists developed a new diagnostic approach to differentiate between DLB, PD and other neuropathies.

There is currently no assay or imaging method available that provides security for clinical diagnosis of Parkinson's disease and atypic Parkinson syndromes. As a consequence, atypic Parkinson syndromes are often misdiagnosed as idiopathic Parkinson disease, which may lead to long-lasting mistherapy. Accordingly, there is an unmet need for methods of differential diagnosis of dementia with Lewy bodies, Parkinson's disease and other non-alpha-synuclein variants with Parkinson-like syndromes.

The provided solution is a new developed diagnostic approach to differentiate between DLB, PD and other neuropathies by:
• extracting exosomes from cerebrospinal fluid (CSF patient samples)
• counting number of exosomes
• measuring the amount of exosomal alpha-synuclein.

Potential applications are:
• Diagnosis of PD using CSF patient samples
• Diagnosis of DLB using CSF patient samples
• Differential diagnosis DLB vs PD and/or vs other non-PD, non-dementia neurological disorders (e.g. PNP, PSP)

The scientists interested in commercialization and are looking for licensing partners in the diagnostic field (in-house diagnostics or diagnostic test kit provider).
Advantages: • Differential diagnosis based on sub-population of widely accepted biomarker alpha-synuclein • Robust diagnosis due to evaluation of “shielded” alpha-synuclein in exosomes • Use of an internal control parameter in patient's samples (number of exosomes) • Differential diagnosis of DLB vs PD with a high sensitivity (>0.85) and... • ...High specificity (>0.80) – more than twice compared to CSF alpha-synuclein (total amount) • Validated on patient's CSF sample in a clinical cohort of >100
Comments: Comments Regarding Stage of Development: The diagnostic test has been validated on patient's CSF sample in a clinical cohort of >100.
RequestId: 52

Sponsors

smartportal sponsors